Search Results - "Shetty, Jeevan"

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial by Platzbecker, Uwe, Della Porta, Matteo Giovanni, Santini, Valeria, Zeidan, Amer M, Komrokji, Rami S, Shortt, Jake, Valcarcel, David, Jonasova, Anna, Dimicoli-Salazar, Sophie, Tiong, Ing Soo, Lin, Chien-Chin, Li, Jiahui, Zhang, Jennie, Giuseppi, Ana Carolina, Kreitz, Sandra, Pozharskaya, Veronika, Keeperman, Karen L, Rose, Shelonitda, Shetty, Jeevan K, Hayati, Sheida, Vodala, Sadanand, Prebet, Thomas, Degulys, Andrius, Paolini, Stefania, Cluzeau, Thomas, Fenaux, Pierre, Garcia-Manero, Guillermo

“…Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk myelodysplastic syndromes but…”
Get full text

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study by Platzbecker, Uwe, Götze, Katharina S, Kiewe, Philipp, Germing, Ulrich, Mayer, Karin, Radsak, Markus, Wolff, Thomas, Chromik, Joerg, Sockel, Katja, Oelschlägel, Uta, Haase, Detlef, Illmer, Thomas, Al-Ali, Haifa Kathrin, Silling, Gerda, Reynolds, Joseph G, Zhang, Xiaosha, Attie, Kenneth M, Shetty, Jeevan K, Giagounidis, Aristoteles

“…JCO Luspatercept has high clinical activity in patients with transfusion-dependent lower-risk myelodysplastic syndromes (LR-MDS) and ring sideroblasts (RS)…”
Get full text

Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion‐dependent thalassemia by Garbowski, Maciej W., Ugidos, Manuel, Risueño, Alberto, Shetty, Jeevan K., Schwickart, Martin, Hermine, Olivier, Porter, John B., Thakurta, Anjan, Vodala, Sadanand

“…Luspatercept, a ligand‐trapping fusion protein, binds select TGF‐β superfamily ligands implicated in thalassemic erythropoiesis, promoting late‐stage erythroid…”
Get full text

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts by Zeidan, Amer M., Platzbecker, Uwe, Garcia-Manero, Guillermo, Sekeres, Mikkael A., Fenaux, Pierre, DeZern, Amy E., Greenberg, Peter L., Savona, Michael R., Jurcic, Joseph G., Verma, Amit K., Mufti, Ghulam J., Buckstein, Rena, Santini, Valeria, Shetty, Jeevan K., Ito, Rodrigo, Zhang, Jennie, Zhang, George, Ha, Xianwei, Backstrom, Jay T., Komrokji, Rami S.

“…Luspatercept is an approved therapy for selected patients with lower risk myelodysplasia requiring transfusion despite erythropoiesis-stimulating agents, based…”
Get full text

Barriers and Enablers for Physical Activity Engagement Among Individuals From India With Type 2 Diabetes Mellitus: A Mixed-Method Study by Matpady, Prabhath, Maiya, Arun G, Saraswat, Pallavi P, Rao, Chythra R, Pai, Mamatha Shivananda, Anupama, Shekarappa D, Shetty, Jeevan K, Umakanth, Shashikiran

“…Type 2 diabetes mellitus (T2DM) is a complex, chronic condition that can cause multiple complications due to poor glycemic control. Self-management plays a…”
Get more information

Management of diabetes mellitus using medicinal plants: A review by Sivakumar, Anupa, Thanu, Amardev Singh, Vishnumukkala, Thirupathirao, Ksv, Angu Bala Ganesh, K Shetty, Jeevan, Jagadeesan, Saravanan, Gopalakrishna, Prarthana Kalerammana

“…Diabetes mellitus has a global impact affecting 422 million individuals and leading to significant health complications. This makes it a pressing global health…”
Get full text

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia by Taher, Ali T, Musallam, Khaled M, Viprakasit, Vip, Kattamis, Antonis, Lord-Bessen, Jennifer, Yucel, Aylin, Guo, Shien, Pelligra, Christopher, Shields, Alan L, Shetty, Jeevan K, Miteva, Dimana, Bueno, Luciana Moro, Cappellini, Maria Domenica

“…ObjectivesThe non-transfusion-dependent beta-thalassaemia-patient-reported outcome (NTDT-PRO) questionnaire was developed for assessing anaemia-related…”
Get full text

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis by Komrokji, Rami S., Platzbecker, Uwe, Fenaux, Pierre, Zeidan, Amer M., Garcia-Manero, Guillermo, Mufti, Ghulam J., Santini, Valeria, Díez-Campelo, María, Finelli, Carlo, Jurcic, Joseph G., Greenberg, Peter L., Sekeres, Mikkael A., DeZern, Amy E., Savona, Michael R., Shetty, Jeevan K., Ito, Rodrigo, Zhang, George, Ha, Xianwei, Backstrom, Jay T., Verma, Amit

Get full text

Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept by Cappellini, Maria Domenica, Taher, Ali T., Piga, Antonio, Shah, Farrukh, Voskaridou, Ersi, Viprakasit, Vip, Porter, John B., Hermine, Olivier, Neufeld, Ellis J., Thompson, Alexis A., Tang, Derek, Yucel, Aylin, Lord‐Bessen, Jennifer, Yu, Peiwen, Guo, Shien, Shetty, Jeevan K., Miteva, Dimana, Zinger, Tatiana, Backstrom, Jay T., Oliva, Esther Natalie

“…Background Patients with transfusion‐dependent (TD) β‐thalassemia require long‐term red blood cell transfusions (RBCTs) that lead to iron overload, impacting…”
Get full text

Receptor for Advanced Glycation End Product, Organ Crosstalk, and Pathomechanism Targets for Comprehensive Molecular Therapeutics in Diabetic Ischemic Stroke by Rao, Nivedita L, Kotian, Greeshma B, Shetty, Jeevan K, Shelley, Bhaskara P, Dmello, Mackwin Kenwood, Lobo, Eric C, Shankar, Suchetha Padar, Almeida, Shellette D, Shah, Saiqa R

“…Diabetes mellitus, a well-established risk factor for stroke, is related to higher mortality and poorer outcomes following the stroke event. Advanced glycation…”
Get full text

Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial by Taher, Ali T, Cappellini, Maria Domenica, Kattamis, Antonis, Voskaridou, Ersi, Perrotta, Silverio, Piga, Antonio G, Filosa, Aldo, Porter, John B, Coates, Thomas D, Forni, Gian Luca, Thompson, Alexis A, Tartaglione, Immacolata, Musallam, Khaled M, Backstrom, Jay T, Esposito, Oriana, Giuseppi, Ana Carolina, Kuo, Wen-Ling, Miteva, Dimana, Lord-Bessen, Jennifer, Yucel, Aylin, Zinger, Tatiana, Shetty, Jeevan K, Viprakasit, Vip, Buaboonnam, Jassada, Ekwattanakit, Supachai, Khunhapinant, Archrob, Loka, Efthalia, Moraki, Maria, Flevari, Pagona, Dimopoulou, Maria, Bartzi, Vasiliki, Daadaa, Hisham, El Hasbani, Georges, Koussa, Suzanne, Ammendola, Federica, Scianguetta, Saverio, Puglia, Marta, Ferrara, Ilaria, Ferrero, Giovanni, Gaglioti, Carmen, Longo, Filomena, Turrini, Silvia, Voi, Vincenzo, Cassinerio, Elena, De, Anna, Graziadei, Giovanna, Marcon, Alessia, Migone De Amicis, Margherita, Motta, Irene, Cinque, Patrizia, Pannone, Bruno, Ricchi, Paolo, Balocco, Manuela, Carrara, Paola, Della Rovere, Francesco, Lamagna, Martina, Pinto, Valeria, Quintino, Sabrina, Eleftheriou, Perla, Garbowski, Maciej, de Kreuk, Arne, Carson, Susan, Denton, Christopher, Hofstra, Tom, Veluswamy, Sayany, Wood, John, Badawy, Sherif, Bercovitz, Rachel, Bhat, Rukhmi, Calamaras, Diane, Liem, Robert, Mack, Astrid

“…BACKGROUNDIn patients with non-transfusion-dependent β-thalassaemia, haemoglobin concentrations lower than 10 g/dL are associated with a higher risk of…”
Get full text

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial by Oliva, Esther Natalie, Platzbecker, Uwe, Garcia-Manero, Guillermo, Mufti, Ghulam J, Santini, Valeria, Sekeres, Mikkael A, Komrokji, Rami S, Shetty, Jeevan K, Tang, Derek, Guo, Shien, Liao, Weiqin, Zhang, George, Ha, Xianwei, Ito, Rodrigo, Lord-Bessen, Jennifer, Backstrom, Jay T, Fenaux, Pierre

“…Patients with myelodysplastic syndromes (MDS) often experience chronic anemia and long-term red blood cell transfusion dependence associated with significant…”
Get full text

Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia by Piga, Antonio, Longo, Filomena, Gamberini, Maria Rita, Voskaridou, Ersi, Ricchi, Paolo, Caruso, Vincenzo, Pietrangelo, Antonello, Zhang, Xiaosha, Shetty, Jeevan K., Attie, Kenneth M., Tartaglione, Immacolata

“…Background: β-thalassemia is a hereditary blood disorder resulting in ineffective erythropoiesis and anemia. Management of anemia with regular blood…”
Get full text

Bisalbuminemia in a Hypothyroid Patient with Diabetes: A Case Report by Shetty, Jeevan K, Maradi, Ravindra, Prabhu, Krishnananda, Bhat, Gopalkrishna

“…Bisalbuminemia is a rarely encountered anomaly characterized by presence of bifid albumin bands or a single widened albumin band in electrophoretogram…”
Get full text

Identifying thresholds for meaningful improvements in NTDT-PRO scores to support conclusions about treatment benefit in clinical studies of patients with non-transfusion-dependent beta-thalassaemia: analysis of pooled data from a phase 2, double-blind, placebo-controlled, randomised trial by Taher, Ali T, Musallam, Khaled M, Viprakasit, Vip, Kattamis, Antonis, Lord-Bessen, Jennifer, Yucel, Aylin, Guo, Shien, Pelligra, Christopher G, Shields, Alan L, Shetty, Jeevan K, Glassberg, Mrudula B, Bueno, Luciana Moro, Cappellini, Maria Domenica

“…Objectives To estimate thresholds for defining meaningful within-patient improvement from baseline to weeks 13–24 and interpreting meaningfulness of…”
Get full text

The experiences of the landslide survivors from Kodagu District, India: Need for community-engaged village/ward level micro disaster management planning by Matpady, Prabhath, Maiya, Arun G., Acharya, Kiran K.V., Anupama, D.S., Bhagavat, Prashanth, Rao, Arathi P., Shetty, Jeevan K.

“…Introduction: Kodagu district in India had catastrophic landslides in 2018, the rarest occurrence known to people until 2018. It has become an annual affair…”
Get full text

PB2535: TRIAL IN PROGRESS: A PHASE 2, DOUBLE‐BLIND, RANDOMIZED, PLACEBO‐CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUSPATERCEPT TO TREAT ANEMIA IN ADULTS WITH ALPHA‐THALASSEMIA by Viprakasit, Vip, Lai, Yongrong, Forni, Gian Luca, Lu, Meng‐Yao, Yang, Liudi, Shi, Wenhui, Medlin, Loyse Felber, Lersch, Frederik, Shetty, Jeevan K., Bueno, Luciana Moro, Wei, Richard, Kattamis, Antonis

Get full text

P1466: EFFECT OF LUSPATERCEPT ON BONE MINERAL DENSITY IN PATIENTS WITH BETA‑THALASSEMIA ENROLLED IN THE PHASE 3 BELIEVE TRIAL by Coates, Thomas D., Domenica Cappellini, Maria, Sheth, Sujit, Kuo, Kevin H.M., Giulio Piga, Antonio, Kattamis, Antonis, Perin, Martina, Lersch, Frederik, Shetty, Jeevan K., Lai, Yinzhi, Kuo, Wen‐Ling, Taher, Ali T.

Get full text

S273: LONG‐TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON‐TRANSFUSION‐DEPENDENT ΒETA‐THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL by Taher, Ali T., Viprakasit, Vip, Domenica Cappellini, Maria, Giulio Piga, Antonio, Porter, John B., Coates, Thomas D., Musallam, Khaled M., Luca Forni, Gian, Shetty, Jeevan K., Bosilkovska Weisskopf, Marija, Wei, Richard, Kuo, Wen‐Ling, Kattamis, Antonis

Get full text

CA-125 and Ceruloplasmin Levels in Ovarian Cancer Patients by Hegde, Mangala, Chianeh, Yousef Rezaei, Shetty, Jeevan, Fernandes, Donald J, Rao, Pragna

“…Purpose: The initial stage of proliferation of epithelial ovarian carcinoma (EOCa) is usually asymptomatic. Due to the lack of sensitive and reliable markers…”
Get full text